Experimental studies of honokiol in combination with artemisinin on anti-tumor effect of SPC-A-1 cells in vitro

Chinese Pharmaceutical Journal

Volumn 46, Issue 21, 2011, Pages 1639-1642

  Wang, Chun Ling ^a   Lai, Xiao Ping ^a   Wu, An Guo ^a  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Artemisinin; Cell cycle; Honokiol; Synergstic effect

Indexed keywords

ARTEMISININ; HONOKIOL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DRUG POTENTIATION; EXPERIMENTAL STUDY; IC 50; IN VITRO STUDY;

EID: 83155193049     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. HIBASAMI H, ACHIWA Y, KATSUZAKI, et al. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells[J]. Int J Mol Med, 1998, 2(6): 671-673.
2. YANG S E, Ming-TSUEN H, et al. Down-modulation of BCL-XL, release of cytochrome c and sequential activation of caspase during honokiol-induced apoptosis in human squamouous lung cancer CH27 cells[J]. Biochem Pharmacol, 2002, 63(9): 1641-1651.
3. BAI X, CERIMELE F, USHIO-FUKAI M, et al. Honokiol, a small molecular weight natural product, inhibits angiogensis in vitro and tumor growth in vivo [J]. J Biol Chem, 2003, 278(37): 35501-35507.
4. WANG T, CHEN F, CHEN Z, et al. Honokiol induces apoptosis through P53 -independent pathway in human colorectal cell line RKO [J]. World J Gastroenterol, 2004, 10(15): 2205-2208.
5. BATTLE T E, ARBISER J, FRANK D A, et al. The natural product honokiol induces caspase -dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cell [J]. Blood, 2005, 106(2): 690-697.
6. ISHITTSUKA K, HIDESHIMA T, HAMASAKI M, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and-independent apoptosis[J]. Blood, 2005, 106(17): 1794-1800.
7. EFFERTH I, DAVEY M, OLBRICH A, et al. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1 or MRP1 overexpressing multidrug-resistant human CCRF-CEM leukemia cells [J]. Blood Cells Mol Dis, 2002, 28(2): 160-168.
8. LAI H, SINGH N P. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a] anthracene (DMBA)-induced breast cancer in the rat [J]. Cancer Lett, 2006, 231(1): 43-48.
9. SINGH N P, LAI H C. Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells [J]. Anticancer Res, 2005, 25(6B): 4325-4331.
10. BERGER T G, DIECKMANN D, EFFERTH T, et al. Artesunate in the treatment of metastatic uveal melanoma first experiences [J]. Oncol Rep, 2005, 14(6): 1599-1603.
11. EFFERTH T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells [J]. Curr Drug Targets, 2006, 7(4): 407-421.
12. HAN R. Anti-Cancer Drug Research and Experiment Technology [M]. Beijing: Beijing Medical University Association with China Xie-he Medical University Press, 2005.
13. JIN Z J. The combination of merger medication [J]. Acta Pharmacol Sin, 1980, 1(2): 70-76.
14. ZHENG E. Tissue Culture Technology and Its Application in Medical Research [M]. Beijing: Peking Uinon Medical University Press, 2004: 358-359.